Evidence map›Paper›PMID 39386340›Full record

ReviewMiddle East journal of digestive diseases2024

An Update on Eradication of

Mahboobe Ebrahimi, Sepehr Tirgar Fakheri, Faezeh Aeeni, Tarang Taghvaei, Mehdi Saberi Firoozi, Hafez Fakheri

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Middle East journal of digestive diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Efficacy of IgY onAntibody therapeutics · 2026
    Article
  2. Addressing the global challenge ofGut microbes reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mahboobe EbrahimiGut and Liver Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0001-5473-282X
Sepehr Tirgar FakheriGut and Liver Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Faezeh AeeniGeneral Physician, Private Clinic, Sari, Iran.
Tarang TaghvaeiGut and Liver Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mehdi Saberi FirooziDigestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Hafez FakheriGut and Liver Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0002-0579-6111

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: This review article consists of randomized controlled trials related to Results: According to our review of Iranian articles regarding first-line Conclusion: Various

Indexed as

Bismuth quadruple therapyConcomitant therapyEradicationHelicobacter pyloriIranResistance

Identifiers

PMID39386340
PMCPMC11459289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.